Company Encyclopedia
View More
name
ClinPlus
301257.SZ
SMO ClinPlus CO.,LTD. provides site management services in research development in pharmaceuticals, medical devices, and health-related products in China. The company’s SMO services include preliminary model establishment, preliminary plan preparation, initiation of clinical trial sites, on-site implementation, and project management services. SMO ClinPlus CO.,LTD.
550.52 B
301257.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Life Sciences Tools and ServicesIndustry
Industry Ranking9/27
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.16%B
    • Profit Margin14.84%A
    • Gross Margin29.11%C
  • Growth ScoreC
    • Revenue YoY1.14%C
    • Net Profit YoY14.58%C
    • Total Assets YoY8.91%B
    • Net Assets YoY9.80%B
  • Cash ScoreC
    • Cash Flow Margin673.89%C
    • OCF YoY1.14%C
  • Operating ScoreB
    • Turnover0.57B
  • Debt ScoreA
    • Gearing Ratio16.69%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ClinPlus released its performance for the first three quarters, with a net profit attributable to the parent company of 87.3815 million yuan, an increase of 20.92%

    ClinPlus released its third-quarter report for 2025, with operating revenue for the first three quarters amounting to 609 million yuan, a year-on-year increase of 2.59%. The net profit attributable to shareholders of the listed company was 87.3815 million yuan, a year-on-year increase of 20.92%. The net profit after deducting non-recurring gains and losses was 69.6744 million yuan, a year-on-year increase of 11.48%. The basic earnings per share were 1.11 yuan

    Zhitong·
    SZ
    301257
    +0.74%
    Zhitong·
    SZ
    301257
    +0.74%

    Zhitong A-share lock-up release overview | October 28

    On October 28th, a total of 5 listed companies had their restricted shares unlocked, with a total market value of approximately 6.034 billion yuan. The specific situation of the restricted share unlock today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlock Shares Shen Machine 000410 Additional A Shares Legal Person Allocation Listed 381 million Yonggui Electric 300351 Equity Incentive Restricted Circulation 451,400 ClinPlus 301257 Equity Incentive Restricted Circulation 292,500 HCFA 688320 4,013,700 Hunan Kylinsec Technology 688152 4,768,000

    Zhitong·
    SZ
    301257
    +0.74%
    SH
    688320
    +7.37%
    SZ
    000410
    +0.92%
    Zhitong·
    SZ
    301257
    +0.74%
    SH
    688320
    +7.37%
    SZ
    000410
    +0.92%

    ClinPlus shareholders view Zhao Tai intends to reduce its holdings by no more than 3%

    According to the Zhitong Finance APP, ClinPlus announced that its shareholder Shanghai Guanyu Investment Development Co., Ltd. Guanyu Zhaotai (Jiaxing) Venture Capital Partnership (Limited Partnership) (hereinafter referred to as "Guanyu Zhaotai") plans to reduce its holdings of the company's shares by no more than 2.3701 million shares (accounting for 3.00% of the company's total share capital) through centralized bidding and/or block trading within three months after 15 trading days from the date of this announcement

    Zhitong·
    SZ
    301257
    +0.74%
    Zhitong·
    SZ
    301257
    +0.74%

    SMO Clinplus Says Key Shareholder Plans To Unload 3% Stake In Three Months

    SMO Clinplus Co Ltd :SAYS KEY SHAREHOLDER PLANS TO UNLOAD 3% STAKE IN THREE MONTHS

    Reuters·
    SZ
    301257
    +0.74%
    Reuters·
    SZ
    301257
    +0.74%

    Innovative drug concept experiences a surge, JOINN hits the daily limit up

    The innovative drug concept has seen a surge in activity. As of the time of writing, JOINN has hit the daily limit, with ClinPlus, Hicin Pharmaceutical, Asymchem, and others following suit

    Zhitong·
    SH
    603127
    -0.07%
    HK
    06127
    +0.31%
    SZ
    301257
    +0.74%
    Zhitong·
    SH
    603127
    -0.07%
    HK
    06127
    +0.31%
    SZ
    301257
    +0.74%
    © 2025 Longbridge｜Disclaimer